The composition is sold as INhance Post-Injection Serum with TriHex Technology. This is the company's fourth patent awarded by the USPTO.
"We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations which is confirmed by its numerous patents. INhance Post-Injection Serum combines the antiaging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state of the art post-procedure recovery and skin enhancing benefits,"
commented Dr Alan Widgerow, MBBCh (MD); MMed (MHS); FCS; FACS and chief medical officer at Alastin.
In June, a clinical study highlighting INhance Post-Injection Serum with TriHex Technology was published by the Journal of Drugs in Dermatology (JDD). In the multi-center, randomized, double-blind clinical study, two bruise models were studied and used to create similar bruises on the subjects' left and right arms. One arm was treated with INhance Post-Injection Serum, while the control arm was treated with a bland moisturizer comparator. The clinical study results demonstrated that participants on day 2 and 3 who used INhance Post-Injection Serum with TriHex Technology had 73% less bruise color intensity and significant improvement over the comparator. Overall, 81% of subjects applying the INhance topically had less bruising on day 2 and 3 than the comparator.
INhance was formulated for use on all areas of the face including the body of the lip, a popular area for injection and more prone to bruising, according to the company.